Do you want to read an article? Please log in or register.
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Leukemia
Related content
Leukemia
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
J Clin Oncol
Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, García-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W
doi: 10.1200/JCO-24-02265
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Leukemia
Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17
Blood
Condoluci A, Romano I, Dietrich D, Pini K, Stussi G, Müller G, Cantoni N, Cathomas R, Mey UJM, Widmer AA, Zenz T, Gregor M, Heim D, Andres M, Benz R, Rossi D
doi: 10.1182/blood.2024026879
Lymphoma
Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL
Leukemia
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
J Clin Oncol
Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM
doi: 10.1200/JCO-25-00166
Leukemia
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia
Leuk Lymphoma
Lévy V, Srivastava T, Gautam R, Swami S, Wang K, Yang K, Mohseninejad L
doi: 10.1080/10428194.2025.2506501
ASH 2024
Lymphoma
Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement
Lymphoma
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Blood
Brooks TR, Zabor EC, Bedelu Y, Yang X MD, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J PharmD, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K MD, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C DO, Khan C, Bliven SP MD, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A MD, Hernandez-Ilizaliturri FJ, Chinyengetere F MDPhD, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT
doi: 10.1182/blood.2025029117
SPECIAL REPORT
Breast Cancer